Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion

Antibodies: At The Nexus of Antigens and Cancer Vaccines

“…Several anti-Lewis Y (LeY)-reactive antibodies have been also tested in the clinic. Most recently, the safety, tolerability, and therapeutic efficacy of the LeY-specific humanized mAb MB311 was evaluated in patients with malignant effusions in a phase 2 clinical trial [28]. What is amazing, from a development perspective, was the relatively short period between antibody discovery, through preclinical assessment; antibody production; and clinical trial testing.…”